SCHEMBL2195641

SCHEMBL2195641

Clc1ccc(CN(I)I)cc1.Cn1c(=[Pt])n(C)c2ccccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 1/20 0.40
SLC5A2 P31639 1/20 0.38
HTT P42858 2/20 0.38
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
MAPK1 P28482 1/20 0.38
ALDH1A1 P00352 2/20 0.38
TNF P01375 1/20 0.36
CXCL8 P10145 1/20 0.36
SOS1 Q07889 1/20 0.36
NOD2 Q9HC29 1/20 0.36
NOD1 Q9Y239 1/20 0.36
GALR3 O60755 1/20 0.36
NR2F2 P24468 1/20 0.36
CXCR3 P49682 4/20 0.35
TSHR P16473 2/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2192488 0.87 ALDH1A1 (0.39) RAB9ANPC1MAPK1ALDH1A1TSHR
SCHEMBL2196641 0.86 NPC1 (0.38) RAB9ASMN1; SMN2KMT2ANPC1HTT
SCHEMBL2196746 0.85 TSPO (0.39) RAB9AKMT2ANPC1ALDH1A1TSHR
SCHEMBL2192106 0.85 CXCR3 (0.46) RAB9AKMT2ANPC1HTTALDH1A1
SCHEMBL2196159 0.84 CYP19A1 (0.39) RAB9ASMN1; SMN2KMT2ANPC1CYP11B1
SCHEMBL2195276 0.81 KIF11 (0.39) KMT2AMEN1LSSHTR6
SCHEMBL2195803 0.80 LSS (0.37) RAB9ANPC1HTTALDH1A1LSS
SCHEMBL2195883 0.79 LMNA (0.42) RAB9ASMN1; SMN2KMT2ANPC1HTT
SCHEMBL2192772 0.78 CYP19A1 (0.34) RAB9ASMN1; SMN2KMT2ANPC1ALDH1A1
SCHEMBL2193567 0.77 CYP11B1 (0.36) SMN1; SMN2KMT2ANPC1CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 RAB9A 1440/4885SMN1; SMN2 4069/4885KMT2A 4286/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 RAB9A 1440/4885SMN1; SMN2 4069/4885KMT2A 4286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.